Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O60266

UPID:
ADCY3_HUMAN

ALTERNATIVE NAMES:
ATP pyrophosphate-lyase 3; Adenylate cyclase type III; Adenylate cyclase, olfactive type; Adenylyl cyclase 3

ALTERNATIVE UPACC:
O60266; B3KT86; Q53T54; Q9UDB1

BACKGROUND:
Adenylate cyclase type 3, known for its alternative names such as Adenylyl cyclase 3, is integral to the biosynthesis of cAMP, a key signaling molecule. This enzyme's function is triggered by G-protein signaling, playing a critical role in odorant signaling cascades and male fertility by ensuring normal sperm motility.

THERAPEUTIC SIGNIFICANCE:
The association of Adenylate cyclase type 3 with obesity, where susceptibility is linked to gene variants, highlights its therapeutic potential. Targeting this protein could lead to innovative treatments for obesity, leveraging its role in cAMP biosynthesis and its impact on insulin levels and fat accumulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.